NCT04497662View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

January 21, 2021

Study Completion Date

March 2, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

KPL-404

humanized IgG4 monoclonal antibody

OTHER

Matching Placebo

Placebo

Trial Locations (2)

4006

Q-Pharm Pty Ltd, Herston

78744

PPD Clinic, Austin

Sponsors
All Listed Sponsors
lead

Kiniksa Pharmaceuticals, Ltd.

INDUSTRY

NCT04497662 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects | Biotech Hunter | Biotech Hunter